Trusopt Drug Interactions

Specific drug interaction studies have not been performed with DORZOLAMIDE HCl (TRUSOPT) Ophthalmic Solution. In clinical studies, DORZOLAMIDE HCl (TRUSOPT) was used concomitantly with the following medications without evidence of adverse interactions: Timolol ophthalmic solution, betaxolol ophthalmic solution and systemic medications, including ACE-inhibitors, calcium channel blockers, diuretics, non-steroidal anti-inflammatory drugs including aspirin, and hormones (e.g. estrogen, insulin, thyroxine).
DORZOLAMIDE HCl (TRUSOPT) is a carbonic anhydrase inhibitor and although administered topically, is absorbed systemically. In clinical studies, DORZOLAMIDE HCl (TRUSOPT) was not associated with acid-base disturbances. However, these disturbances have been reported with oral carbonic anhydrase inhibitors and have in some instances, resulted in drug interactions (e.g. toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving DORZOLAMIDE HCl (TRUSOPT).